Clinical Trials Info:

Basal Cell Carcinoma Clinical Studies

A Multicenter, Randomized, Double-blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects with Basal Cell Nevus Syndrome

Enrollment status: Open

In this study, patidegib topical gel is being evaluated as a topical (applied to skin) treatment for BCNS. The main purpose of this study is to see if the study gel, which is applied to the face, reduces the number of new surgically eligible BCCs and learn more about the safety of the study gel. This information will be obtained by taking samples of your blood and urine, collection of medical exams performed by the study doctor, collection of images of your facial area, and by taking biopsies (tissue samples) of your skin. 

Study coordinator: Aaron Rankin, (734) 936-7519 or dermtrials@med.umich.edu
Please reference Derm #: 729

Understanding the effects of anti-basal cell carcinoma drugs on taste and smell

Enrollment status: Open

Basal cell carcinoma (BCC) is caused by abnormal activity of a group of proteins called the Hedgehog pathway, and this leads to uncontrolled growth of BCC tumor cells. The Hedgehog pathway is important in many cells and organs during development and normally works like an “on-off” switch: it makes sure that developing tissues grow or mature appropriately at certain times, and at other times, the tissues stop growing or maturing. The Hedgehog pathway is turned off in most adult cells, but in BCC, the “on-off” switching mechanism is broken and the Hedgehog pathway is turned on ‘permanently’ in some skin cells, which grow into a BCC tumor. Drugs like vismodegib (Erivedge) and other Hedgehog pathway inhibitors (HPIs) effectively block the cancer-causing Hedgehog pathway signal, leading to a reduction in BCC tumor size and possibly even tumor disappearance. However, patients eventually develop side effects while taking vismodegib and other HPIs, including muscle cramps, hair loss, and changes in their ability to taste. The purpose of this study is to learn more about how vismodegib and other HPIs may change your ability to taste things, and to determine if you also develop changes in how things smell.

Study coordinator: Aaron Rankin, (734) 936-7519 or dermtrials@med.umich.edu
Please reference Derm #: 672